✦ LIBER ✦

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis

✍ Scribed by Margaret Rosenfeld; Ron Gibson; Sharon McNamara; Julia Emerson; Karen S. McCoyd; Richard Shell; Drucy Borowitz; Michael W. Konstan; George Retsch-Bogart; Robert W. Wilmott; Jane L. Burns; Paolo Vicini; A.Bruce Montgomery; Bonnie Ramsey

Book ID: 117847881
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 114 KB
Volume: 139
Category: Article
ISSN: 1097-6833
DOI: 10.1067/mpd.2001.117785

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Falsely elevated serum tobramycin concen

Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin

✍ Okan Elidemir; Stephanie R. Maciejewski; Christopher M. Oermann 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 1 views

A recently developed tobramycin preparation for inhalation (TOBIா, Pathogenesis Corp., Seattle, WA) is widely used in CF patients. It is often used in conjunction with intravenous tobramycin. Renal and ototoxicity associated with the use of tobramycin require that serum drug concentrations be monito

Lower respiratory illness in infants and

Lower respiratory illness in infants and young children with cystic fibrosis

✍ Robert S. Tepper; H. Eigen; J. Stevens; C. Angelicchio; J. Kisling; W. Ambrosius 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 2 views

The purpose of our study was to assess the effect on pulmonary function of adding intravenous hydrocortisone to the standard treatment of infants with cystic fibrosis (CF) hospitalized for lower respiratory illnesses (LRI). Twenty CF infants were randomized and received 10 days of hydrocortisone (10